HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frédéric Simonin Selected Research

Pain (Aches)

1/2022Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization.
6/2021Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.
9/2018A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
1/2017RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
4/2016RF-amide neuropeptides and their receptors in Mammals: Pharmacological properties, drug development and main physiological functions.
7/2014Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities.
12/2013Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
1/2006RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia.
3/2002Two faces for an opioid peptide--and more receptors for pain research.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frédéric Simonin Research Topics

Disease

13Hyperalgesia
04/2024 - 01/2006
9Pain (Aches)
01/2022 - 03/2002
5Chronic Pain
01/2022 - 01/2006
3Respiratory Insufficiency (Respiratory Failure)
04/2024 - 01/2016
2Hypersensitivity (Allergy)
01/2017 - 12/2016
1Obesity
06/2017
1Neuralgia (Stump Neuralgia)
01/2016
1Sleep Wake Disorders
01/2014

Drug/Important Bio-Agent (IBA)

13Opioid Analgesics (Opioids)IBA
01/2022 - 01/2006
10Analgesics (Analgesic Drugs)IBA
10/2021 - 01/2014
6Morphine (MS Contin)FDA LinkGeneric
04/2024 - 12/2013
5Opiate AlkaloidsIBA
11/2018 - 01/2014
5phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamideIBA
11/2018 - 01/2006
4Fentanyl (Sublimaze)FDA LinkGeneric
10/2021 - 01/2017
4neuropeptide FF receptorIBA
11/2018 - 01/2006
4AmidesIBA
01/2017 - 12/2013
4Peptides (Polypeptides)IBA
04/2016 - 12/2013
2DipeptidesIBA
10/2021 - 11/2018
2LigandsIBA
11/2018 - 01/2016
1((3- methoxythiophen- 2- yl)methyl)((2- (9- (pyridin- 2- yl)- 6- oxaspiro(4.5)decan- 9- yl)ethyl))amineIBA
04/2024
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
10/2021
1NeuropeptidesIBA
10/2021
1pimagedine (aminoguanidine)IBA
11/2018
1HydrazonesIBA
11/2018
1Oxycodone (Oxycontin)FDA LinkGeneric
09/2018
1Hormones (Hormone)IBA
06/2017
1morphine-3-glucuronideIBA
01/2017
1mu Opioid Receptors (mu Opioid Receptor)IBA
01/2017
1NociceptinIBA
01/2016
1OrnithineIBA
03/2015
1PeptidomimeticsIBA
03/2015
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2014
1MT1 Melatonin ReceptorIBA
01/2014
1Heroin (Diamorphine)IBA
01/2006
1Opioid Peptides (Opioid Peptide)IBA
03/2002

Therapy/Procedure

5Analgesia
01/2022 - 12/2013